New drug trial aims to free MDS patients from frequent blood transfusions
NCT ID NCT06113302
Summary
This study is testing whether the drug luspatercept can help patients with a lower-risk form of myelodysplastic syndromes (MDS), a bone marrow disorder. The main goal is to see if the drug can safely reduce or eliminate the need for regular blood transfusions in these patients. Researchers will enroll about 40 adults with MDS to monitor their response to the treatment over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.